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sex ‑matched control group consisting of 28 HFrEF 
patients treated with ACEIs. Both groups were fol‑
lowed up for 12 months and all patients had blood 
samples collected for biomarker tests at baseline 
as well as at 3 and 12 months. We analyzed the fol‑
lowing serum markers of collagen synthesis: pro‑
collagen type I carboxyterminal propeptide and 
procollagen type III aminoterminal propeptide 
(PICP and PIIINP; Cloud Clone Corp. Houston, 
Texas, United States), and fibrosis controlling 
factors: transforming growth factor β1 (TGF ‑β1; 
Diaclone SAS, Besancon Cedex, France) and con‑
nective tissue growth factor (CTGF; Cloud Clone 
Corp., Houston, Texas, United States). The study 
was approved by an appropriate ethics commit‑
tee, and patients provided written informed con‑
sent to participate in the study.
Statistical analysis Statistical analyses were per‑
formed using the Statistica PL software (Dell Inc., 
Round Rock, Texas, United States). The signifi‑
cance level was set at 0.05. Normality of variable 
distribution was assessed with the Shapiro–Wilk 
test. In both study groups, continuous data were 
compared using the t test or the Mann–Whitney 
test, as appropriate, whereas categorical val‑
ues, with the χ2 test. Blood levels of fibrosis 
biomarkers were compared at specific and pre‑
defined time points, ie, at baseline and at 3 and 
12 ‑month follow ‑up. Both groups (ie, ARNI‑ and 
Introduction Myocardial fibrosis (MF) plays a cru‑
cial role in cardiac remodeling during the course 
of heart failure with reduced ejection fraction 
(HFrEF).1 The dynamics of MF may be indirectly 
assessed by measuring the levels of circulating se‑
rum markers of fibrosis.2 The clinical use of mul‑
tilevel neurohormonal blockers (eg, β ‑adrenergic 
blockers) and antagonists of the renin–angio‑
tensin–aldosterone system (eg, angiotensin‑
‑converting enzyme inhibitors [ACEIs], angio‑
tensin receptor blockers [ARBs], and mineralocor‑
ticoid receptor antagonists) show numerous ben‑
eficial effects in HFrEF as well as attenuates MF.3 
A recently introduced class of agents—angioten‑
sin receptor–neprilysin inhibitors (ARNIs)—has 
proven to be superior in patients with HFrEF of 
various etiologies in comparison to ACEIs and 
ARBs; however, the role of ARNI treatment in 
MF remains poorly understood.4-6
In this study, we investigated the kinetics of 
serum fibrosis markers in ARNI ‑treated patients 
with HFrEF and compared the results with a con‑
trol group of HFrEF patients treated with ACEIs.
Methods It was a nonrandomized, prospective, 
observational, longitudinal open ‑label study 
with a control group. From January 2017 to 
November 2018, we included 28 patients with 
HFrEF who started ARNI therapy. Patients treat‑
ed with ARNIs were compared with an age‑ and 
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The  baseline median (IQR) values of se‑
rum markers of collagen synthesis were simi‑
lar for patients treated with ARNIs and ACEIs: 
PICP—0.09 (0.07–0.32) ng/ml in the ARNI group 
and 0.15 (0.1–0.25) ng/ml in the ACEI group 
(P = 0.41); and PIIINP—2537.7 (1873.8–9413.4) 
pg/ml in the ARNI group and 3043.7 (2923.9–
5454.9) pg/ml in the ACEI group (P = 0.58). How‑
ever, over the follow ‑up period, PICP levels were 
significantly lower in patients treated with ARNIs 
(at 3 months: 0.09 [0.08–0.21] ng/ml in the ARNI 
group and 0.23 [0.18–0.28] ng/ml in the ACEI 
group; at 12 months: 0.1 [0.08–0.22] ng/ml in 
the ARNI group and 0.34 [0.29–0.36] ng/ml in 
the ACEI group; all P <0.01) (FIguRE 1A). The lev‑
els of PIIINP were similar at 3 months in patients 
treated with ARNIs and ACEIs (2949.6 [1 359.7–
10 437.9] pg/ml vs 4084.2 [3182.9–4642.1] pg/ml; 
P = 0.89); however, at 12 months, PIIINP lev‑
els were significantly higher in patients receiv‑
ing ARNIs compared with those treated with 
ACEIs (3471.2 [1 962.9–12 546.1] pg/ml vs 1299.2 
[809.8–2875.9] pg/ml; P <0.021) (FIguRE 1B).
The median (IQR) levels of TGF‑β1 were sig‑
nificantly lower in the ARNI group compared 
with the ACEI group at each time point dur‑
ing the follow ‑up period, including at baseline 
(783.8 [693.5–907] pg/ml in the ARNI group 
vs 227 [1809–2787] pg/ml in the ACEI group 
[P <0.001]); at 3 months (769.1 [697–831.8] pg/ml 
in the ARNI group vs 2226 [1816‑3145] pg/ml in 
the ACEI group [P <0.001]); and at 12 months 
(776.5 [722‑934] pg/ml in the ARNI group vs 1031 
[763‑2055] pg/ml in the ACEI group [P <0.002]) 
(FIguRE 1C). The median (IQR) levels of CTGF 
were similar at baseline (2.9 [2.38–10.7] ng/ml 
in the ARNI group and 3.4 [2.8–6.2] ng/ml in 
the ACEI group [P = 0.8]) and at 3 months (2.75 
[2.3–6.9] ng/ml in the ARNI group and 3 [2.3–
6.1] ng/ml in the ACEI group [P = 0.92]). Interest‑
ingly, at 12 months, CTGF was found to be signif‑
icantly higher in the ARNI group (median [IQR], 
4.3 [2.7–11.3] ng/ml) in comparison to the ACEI 
group (2.6 [2.2–3.2] ng/ml) (P <0.002) (FIguRE 1D).
Discussion So far, only 3 studies have addressed 
the issue of ARNI treatment with regard to MF in 
patients with HF: 2 studies on HFrEF (both be‑
ing subanalyses of the landmark PARADIGM ‑HF 
(Prospective Comparison of ARNI with ACEI to 
Determine Impact on Global Mortality and Mor‑
bidity in Heart Failure) trial, although with pop‑
ulations of slightly different sizes),and a single 
study on HF with preserved EF (HFpEF).6-8 Simi‑
lar to our study, these studies investigated MF by 
means of a variety of circulating markers of fibro‑
sis. In the first subanalysis of the PARADIGM ‑HF 
trial, Zile et al7 observed that, after 8 months of 
ARNI therapy, the levels of circulating fibrosis‑
‑bound biomarkers, including soluble suppres‑
sion of tumorigenicity 2 (sST2), matrix metal‑
loproteinases (MMP ‑2 and MMP ‑9), tissue in‑
hibitor of matrix metalloproteinase, galectin ‑3 
(Gal ‑3), N ‑terminal propeptide of collagen I, and 
ACEI ‑treated patients) were matched by propen‑
sity score matching according to age and sex. Val‑
ues were expressed as median (interquartile range 
[IQR]) or mean (SD) values, whereas nominal vari‑
ables, as numbers and percentages.
Results Both study groups were matched with 
the following crucial variables: age (mean [SD]: 
ARNI group, 52.9 [15.3] years vs ACEI group, 49.3 
[11.6] years; P = 0.23) and male sex (ARNI group, 
21 [75%] vs ACEI group, 24 [87%]; P = 0.51). In 
addition, other clinically relevant parameters were 
also similarly distributed between the groups: 
New York Heart Association class (class I: ARNI 
group, 1 [3.6%] vs ACEI group, 3 [10.7%]; class 
II: ARNI group, 15 [53.6%] vs ACEI group, 11 
[39.3%]; class III: ARNI group, 12 [42.9%] vs 
ACEI group, 12 [42.9%]; class IV: ARNI group, 
0 vs ACEI group, 2 [7.1%]; P = 0.4), ejection frac‑
tion (mean [SD]: ARNI group, 24.7% [7.6%] vs 
ACEI group, 21.8% (8.3%); P = 0.16), and N ‑termi‑
nal fragment of the prohormone brain natriuret‑
ic peptide levels (mean [SD]: ARNI group, 2156.6 
(1478) pg/ml vs ACEI group, 2493 (1872) pg/ml; 
P = 0.6). The detailed baseline characteristics of 
the ARNI and ACEI groups, respectively, were 
as follows: mean (SD) body mass index—25.3 
(10.8) kg/m2 and 27.1 (5.2) kg/m2 (P = 0.65); hy‑
pertension—11 (40.7%) and 14 (50%) (P = 0.49); 
diabetes—11 (40.7%) and 4 (14.3%) (P = 0.03); 
dyslipidemia—15 (55.6%) and 10 (35.7%) (P = 
0.14); smoking—8  (29.6%) and 15 (53.6%) 
(P = 0.07); atrial fibrillation—9 (32.1%) and 6 
(21.4%) (P = 0.36); QRS width—137.3 (40.4) ms 
and 109.6 (36.8) ms (P = 0.15); mean (SD) left ven‑
tricular end ‑diastolic diameter—67.1 (9.1) mm 
and 71.5 (15.9) mm (P = 0.19); mean (SD) left 
ventricular end ‑diastolic volume—251.7 (106.7) 
ml and 279.8 (151.7) ml (P = 0.44); the median 
(IQR) ratio of early mitral inflow velocity (E wave) 
to early myocardial diastolic velocity (E/E’)—11.5 
(10.7–18.5) and 20 (12.3–26.4) (P = 0.01); pulmo‑
nary artery systolic pressure—32.5 (15.9) mm Hg 
and 30.4 (14.2) mm Hg (P = 0.63); mean (SD) he‑
moglobin level—13.8 (1.8) g/dl and 14.4 (1.6) g/dl 
(P = 0.17); median (IQR) creatinine level—95.5 
(78.2–124.7) μmol/l and 87.5 (69.5–104) μmol/l 
(P = 0.69); median (IQR) high ‑sensitivity C ‑reac‑
tive protein level—2.6 (0.32–5.3) mg/l and 3.7 
(1.1–6.5) mg/l (P = 0.37). The following drugs 
were used for HF therapy: β ‑blockers—in 28 pa‑
tients (100%) in the ARNI group and in 28 pa‑
tients (100%) in the ACEI group (P = 1); miner‑
alocorticoid receptor antagonists—25 (89.3%) 
in the ARNI group and 24 (85.7%) in the ACEI 
group (P = 0.69); loop diuretics—17 (60.7%) in 
the ARNI group and 19 (69.7%) in the ACEI group 
(P = 0.58); digoxin—6 (22.2%) in the ARNI group 
and 5 (17.9%) in the ACEI group (P = 0.69); im‑
plantable cardioverter ‑defibrillator—11 (39.3%) 
in the ARNI group and 10 (35.7%) in the ACEI 
group (P = 0.85); and cardiac resynchroniza‑
tion therapy— 5 (17.9%) in the ARNI group and 
4 (14.3%) in the ACEI group (P = 0.85).
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environment of randomized controlled trials. 
The obvious limitation of our study, which should 
be acknowledged, is that it was based on a much 
smaller study population than used in any ran‑
domized controlled trial. In addition, the in‑
creased risk of false ‑positive results when com‑
paring laboratory data at different time points 
should also be considered. Nonetheless, our study 
focused on previously unstudied biomarkers of 
fibrosis (in this context), such as PICP (a poten‑
tial marker of collagen type I synthesis) as well 
as TGF ‑β1 and CTGF. Collagen type I and III is 
the major component of myocardial fibrous tis‑
sue, and its ratio is distorted during MF in HFrEF 
(ie, there is an excess of collagen type I at the 
expense of collagen type III). Collagen type I, 
PIIINP, decreased to a greater degree in the ARNI 
group compared with the enalapril group. In 
a similar analysis, authors from the same group 
confirmed more pronounced reductions of sST2 
levels in ARNI ‑treated patients and an associa‑
tion between baseline sST2 levels and outcomes.7 
The effect of ARNIs on 4 fibrosis biomarkers: 
sST2, Gal ‑3, MMP ‑2, and PIIINP in patients with 
HFpEF was studied by the PARAMOUNT inves‑
tigators; however, in contrast to the findings ob‑
tained in HFrEF patients, ARNI treatment did 
not influence the blood levels of the measured 
biomarkers.8
Thus, this is the first report on the poten‑
tial effects of ARNI therapy on MF in patients 
with HFrEF outside of the highly controlled 
FIguRE 1 The 12 ‑month kinetics of the serum markers of fibrosis in patients treated with angiotensin receptor–neprilysin inhibitors (ARNIs) and 
angiotensin ‑converting enzyme inhibitors (ACEIs): A –procollagen type I carboxy terminal propeptide (PICP); B – procollagen type III aminoterminal 
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being stronger and less elastic, leads to a stiff‑
er and less compliant left ventricle, whereas col‑
lagen type III is more elastic and compliant.9,10 
Therefore, the gradual increase of PICP levels 
(over the follow ‑up period) in patients treated 
with ACEIs indicated the ongoing overproduc‑
tion of collagen type I, whereas ARNI ‑treated 
patients had a sustained attenuation of collagen 
type I production. On the other hand, the pro‑
duction of collagen type III seems to gradually 
rise in ARNI ‑treated patients over a long peri‑
od of time, whereas it remains at the same lev‑
el in the ACEI treatment group. In brief, 2 dia‑
metrically opposed patterns emerge in terms of 
collagen type I and III synthesis: one pattern is 
seen in ARNI ‑treated patients, characterized by 
low collagen type I synthesis and increased syn‑
thesis of collagen type III; conversely, in ACEI‑
‑treated patients, an increase in collagen type I 
synthesis and a decrease in collagen type III pro‑
duction are observed.
Regarding fibrosis controlling factors, it is more 
challenging to elucidate this issue, as TGF‑β1 val‑
ues were initially significantly higher in the ACEI 
group and this effect persisted during the follow‑
‑up, ie, TGF ‑β1 levels were higher at 3 and 12 
months. Finally, CTGF levels seemed to rise in 
the ARNI group over a long period of time, since 
we noted that CTGF values differed between 
the study groups only at 12 months. However, 
the true significance of these TGF‑β1 and CTGF 
patterns in patients receiving ARNIs and ACEIs 
is far from clear and, as such, it is difficult to in‑
terpret these findings at this stage. The initial 
experience with ARNI therapy in HFrEF is very 
encouraging and further research is needed to 
elucidate the mechanisms of its action, such as 
fibrosis ‑attenuating effects.11
Conclusions In summary, we investigated the po‑
tential role of ARNIs in MF in a real ‑world setting 
and observed that treatment with ARNIs may po‑
tentially improve the distorted ratio of collagen 
type I and III synthesis. This, in turn, may trans‑
late into favorable changes in the morphology and 
function of the left ventricle in HFrEF.
ARTICLE InFoRMATIon
ACknowLEDgMEnTS This study was funded by the Department of Sci‑
entific Research and Structural Funds of Jagiellonian University Medical Col‑
lege (grant no.; N41/DBS/000307; to PR).
ConFLICT oF InTEREST PR received consultant honoraria from Novar‑
tis. Other authors declare no conflict of interest.
opEn ACCESS This is an Open Access article distributed under the terms 
of the Creative Commons Attribution ‑NonCommercial ‑ShareAlike 4.0 Inter‑
national License (CC BY ‑NC ‑SA 4.0), allowing third parties to copy and re‑
distribute the material in any medium or format and to remix, transform, and 
build upon the material, provided the original work is properly cited, distrib‑
uted under the same license, and used for noncommercial purposes only. For 
commercial use, please contact the journal office at pamw@mp.pl.
How To CITE Wiśniowska ‑Śmiałek S, Dziewięcka E, Holcman K, et al. Com‑
parison of the 12 ‑month kinetics of the serum markers of fibrosis between treat‑
ment with angiotensin receptor–neprilysin inhibitors and angiotensin ‑converting 
enzyme inhibitors in patients with heart failure with reduced ejection fraction. Pol 
Arch Intern Med. 2020; 130: 1017‑1020. doi:10.20452/pamw.15599
